Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials were unlikely to

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE